AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 roku życia.
- •Pacjenci z dodatnim wynikiem badania na obecność białka CLDN18.2.
- •Pacjenci z co najmniej jedną zmianą nowotworową widoczną w badaniach obrazowych.
- •Stan ogólny pacjenta pozwalający na aktywność (ECOG 0-1) bez pogorszenia w ciągu ostatnich 2 tygodni.
- •Przewidywana długość życia pacjenta wynosi co najmniej 12 tygodni.
- •Wystarczająca wydolność narządów i szpiku kostnego.
- •Waga ciała powyżej 35 kg.
✗ Disqualifies
- •Aktywna lub niestabilna choroba wrzodowa żołądka lub dwunastnicy.
- •Krwawienie z przewodu pokarmowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (52)
Research Site
Orange, United States
Research Site
Palo Alto, United States
Research Site
Santa Rosa, United States
Research Site
Louisville, United States
Research Site
Commack, United States
Research Site
Providence, United States
Research Site
Houston, United States
Research Site
Melbourne, Australia
Research Site
Murdoch, Australia
Research Site
Randwick, Australia
Research Site
Kingston, Canada
Research Site
Toronto, Canada
Research Site
Montreal, Canada
Research Site
Sherbrooke, Canada
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Tbilisi, Georgia
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Kitaadachi-gun, Japan
Research Site
Kōtoku, Japan
Research Site
Nagoya, Japan
Research Site
Osakasayama-shi, Japan
Research Site
George Town, Malaysia
Research Site
Johor Bahru, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuala Selangor, Malaysia
Research Site
Kuching, Malaysia
Research Site
Chisinau, Moldova
Research Site
Krakow, Poland
Research Site
Warsaw, Poland
Research Site
Bukit Merah, Singapore
Research Site
Singapore, Singapore
Research Site
Singapore, Singapore
Research Site
Singapore, Singapore
Research Site
Gyeonggi-do, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Glasgow, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
London, United Kingdom
Research Site
Oxford, United Kingdom
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.